TET2 and neoplasm: Found a favorable immunogenicity characteristics (HLA—I/II diversity) and tumor risk change (PIK3CA and TET2 mutation) and the effect of chemotherapy unite against PD‐1. The patients were classified into three subtypes: EGIC1, EGIC2 and EGIC3